Discontinuation of Hypomethylating Agent Therapy in Patients with Myelodysplastic Syndromes or Acute Myelogenous Leukemia in Complete Remission or Partial Response: Retrospective Analysis of Survival after Long-term Follow-up

Hypomethylating agents (HMA), such as 5-azacitidine or decitabine, are currently used to treat patients with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML) until treatment failure. However, the outcomes for patients who discontinue therapy after achieving partial response (PR) or co...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Leuk Res
Main Authors: Cabrero, Monica, Jabbour, Elias, Ravandi, Farhad, Bohannan, Zach, Pierce, Sherry, Kantarjian, Hagop M., Garcia-Manero, Guillermo
Formato: Artigo
Idioma:Inglês
Publicado em: 2015
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4826042/
https://ncbi.nlm.nih.gov/pubmed/25828745
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.leukres.2015.03.006
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados